Scitop Bio(300858)2024-04-24 11:18Financial Performance - The company's operating revenue for Q1 2024 was ¥59,025,584.73, a decrease of 18.19% compared to ¥72,147,839.92 in the same period last year[5]. - Net profit attributable to shareholders for Q1 2024 was ¥18,516,444.83, down 7.66% from ¥20,051,536.52 year-on-year[5]. - Basic and diluted earnings per share both decreased by 12.50% to ¥0.07 from ¥0.08 in the previous year[5]. - The operating profit for Q1 2024 was CNY 22,223,701.62, down from CNY 23,589,760.97 in the same period last year, reflecting a decline of 5.79%[23]. - The total profit for Q1 2024 was CNY 22,226,337.31, compared to CNY 23,591,712.00 in Q1 2023, reflecting a decline of 5.79%[23]. - The company’s total comprehensive income for Q1 2024 was CNY 18,516,444.83, down from CNY 20,051,536.52 in Q1 2023, indicating a decrease of 7.66%[23]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 25.50% to ¥28,714,195.39, compared to ¥22,879,324.70 in Q1 2023[5]. - Cash flow from operating activities generated a net amount of CNY 28,714,195.39, an increase of 25.5% compared to CNY 22,879,324.70 in Q1 2023[26]. - Cash flow from investing activities showed a net inflow of CNY 59,957,195.27, a significant improvement from a net outflow of CNY -691,957,796.85 in the previous year[27]. - Total cash and cash equivalents at the end of Q1 2024 amounted to CNY 273,737,504.09, up from CNY 203,598,522.82 at the end of Q1 2023, indicating a growth of 34.3%[27]. - The company reported a significant increase in cash and cash equivalents, rising by 42.90% to ¥273,787,504.09 from ¥191,596,438.14 at the end of 2023[9]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,805,322,040.43, a slight decrease of 0.26% from ¥1,810,100,800.90 at the end of the previous year[5]. - Total liabilities decreased to CNY 53,804,467.79, down 30.2% from CNY 77,099,673.09 in the previous period[20]. - The total equity attributable to shareholders increased to CNY 1,751,517,572.64, up from CNY 1,733,001,127.81, reflecting a growth of 1.1%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,560[13]. - The largest shareholder, Sun Tiansong, holds 19.94% of shares, totaling 52,538,822 shares[13]. - The second-largest shareholder, Ningbo Kerongda Venture Capital Partnership, holds 10.23% of shares, totaling 26,960,866 shares[13]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 36%[13]. - The company has no preferred shareholders as of the reporting period[14]. - There are no changes in the status of the top ten shareholders regarding margin trading[13]. Operational Changes - Accounts receivable decreased by 36.55% to ¥41,494,518.04, primarily due to changes in the sales structure[9]. - The company reported a significant reduction in accounts receivable, which decreased to CNY 41,494,518.04 from CNY 65,395,480.10, a decline of 36.5%[19]. - The company recorded a substantial increase in asset disposal gains of 56,279.38% to ¥568,552.16, compared to a loss of ¥1,012.03 in the previous year[10]. - The company incurred a total operating cash outflow of CNY 59,362,363.01, a decrease of 42.7% compared to CNY 103,717,506.40 in Q1 2023[26]. Research and Development - Research and development expenses increased to CNY 8,008,843.89, up 23.3% from CNY 6,493,526.51 in the previous year[22]. - The company is focusing on expanding its research and development efforts, as indicated by the increase in R&D expenses[22]. Stock Incentive Plan - The company approved a stock incentive plan during the board meeting on February 2, 2024[16]. - The stock incentive plan was also approved at the first extraordinary general meeting on April 8, 2024[16].